Use of chemo-radiotherapy in locally advanced non-small cell lung cancer

European Journal of Cancer

Volumn 38, Issue 2, 2002, Pages 292-299

  Novello, S ^a   Le Chevalier, T ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Non small cell lung cancer; Radiotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IRINOTECAN; MITOMYCIN C; NAVELBINE; PACLITAXEL; VINDESINE;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MULTIMODALITY CANCER THERAPY; NONHUMAN; PATIENT CARE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT FAILURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS;

EID: 0036172844     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00359-8     Document Type: Article

References (54)

1. Cancer statistics, 1998
2. Revisions in the International System for Staging Lung Cancer
3. Prognostic value of pleural effusion in patients with non-small cell lung cancer
4. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-small-cell lung carcinoma: Report by the Radiation Therapy Oncology Group
5. Results of high dose thoracic irradiation incorporatine beam's eye view display in non-small cell lung cancer: A retrospective mulivariate analysis
6. Response toxicity failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials for sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung
7. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with 69.6 Gy in favorable patients with Radiation Therapy Oncology Group 83-11
8. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: A randomized multicentre trial
9. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer
10. High-dose hyperfractionated accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: Unusual toxicity and promising early results
11. Dose escalation in non-small cell lung cancer (NSCLC) using conformal 3-dimensional radiation therapy (C3DRT): Update of a phase I trial
12. Role of radiotherapy in combined modality treatment of locally advanced non-small cell lung cancer
13. Treatment of locally advanced and metastatic non-small cell lung cancer
14. A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III non-small cell lung cancer
15. Improved survival in stage III non-small-cell lung cancer: Seven year follow-up of cancer and leukemia group B (CALGB) 8433 trial
16. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced unresectable non-small-cell lung cancer
17. ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: A randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement de Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists
18. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell carcinoma
19. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
20. Turning up the heat on non-small cell lung cancer: Is the toxicity of concurrent cisplatin-based chemotherapy and accelerated fractionation accettable?
21. Rational integration of radiation and chemotherapy in patients with unresectable stage IIIA or IIIB NSCLC
22. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer: Radiation Therapy Oncology Group Protocol 91-06
23. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer
24. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer
25. Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: Long-term follow-up results
26. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer
27. Radiosensitization with carboplatin for patients with unresectable stage III non-small cell lung cancer: A phase III trial of the Cancer Leukemia Group B and tha Eastern Cooperative Oncology Group
28. A randomized phase III study of concurrent vs sequential thoracic radiotherapy (TRT) in combination with mitomycin (M) vindesine (V) and cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC): Preliminary analysis
29. Phase III study of concurrent vs sequential thoracic radiotherapy (TRT) in combination with Mitomycin (M) Vindesine (V) and Cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC): Five year median follow-up results
30. Phase III comparison of sequential vs concurrent chemoradiation for patients (Pts) with unresected stage III non-small cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410
31. Simultaneous paclitaxel and radiotherapy: Initial clinical experience in lung cancer and other malignancies
32. Weekly Paclitaxel/Cisplatin with concurrent radiotherapy in patients with locally advanced non-small cell lung cancer: A phase I study
33. Phase II trial of weekly paclitaxel, carboplatin and simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC)
34. Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy (TRT) for locally advanced non-small cell lung cancer (NSCLC): Three year follow-up
35. Concurrent paclitaxel carboplatin and radiation therapy for locally advanced non-small cell lung cancer
36. Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small cell lung cancer
37. Induction platinum-based chemotherapy followed by radical hyperfractionated radiotherapy with concurrent chemotherapy in the treatment of locally advanced non-small cell lung carcinoma of the lung
38. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: Report of Fox Chase Cancer Center Study 94-001
39. Initial report of locally advanced multimodality protocol (LAMP): ACR 427: A randomized 3-arm phase II study of paclitaxel (T), carboplatin®, and thoracic radiation (TRT) for patients with stage III non small cell lung cancer (NSCLC)
40. Positive phase II results of RSR13 and concurrent radiation therapy after induction chemotherapy with paclitaxel and carboplatin for locally advanced inoperable non-small cell lung cancer
41. CALGB study 9431: A randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC)
42. Phase I trial of outpatient weekly docetaxel (DTX) carboplatin (CBDCA) and concurrent thoracic radiation therapy (TRT) for stage III unresectable non-small-cell lung cancer: A Vanderbilt Cancer Center affiliate network (VCCAN) trial
43. Gemzar (Gemcitabine) with thoracic radiotherapy - A phase II pilot study in chemonaive patients with advanced non-small cell lung cancer (NSCLC)
44. Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: A phase I study
45. A phase II study of concurrent multidose vinorelbine with definitive radiation therapy for inoperable stage III non-small cell lung cancer
46. A randomized phase II trial with concurrent versus sequential radiochemotherapy in non small cell lung cancer
47. Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) with concurrent thoracic radiotherapy (TRT) in locally advanced non-small cell lung cancer (NSCLC)
48. Navelbine (NVB)-cisplatin (CDDP) induction chemotherapy (ICT) followed by radiation with or without daily carboplatin (CBDCA) in locally advanced unresectable non small cell lung cancer: Intermediate analysis of a french, multicenter phase III randomized trial
49. SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumors
50. Survival benefit from Tirazone (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: Final results from the international phase III CATAPULT I trial
51. Concurrent weekly paclitaxel and radiation therapy for locally advanced non-small cell lung cancer
52. Twice-weekly paclitaxel and radiation for stage III non-small cell lung cancer
53. Phase I/II study of paclitaxel and radiotherapy in non-small cell lung cancer